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Undoubtedly, the pharmaceutical industry, both within the United States 
and globally, is significant to a large portion of the population. “Pharmaceuticals 
save lives, relieve suffering, and promote the quality of life for those with access to 
them.”2 In 2019, United States spending on pharmaceuticals topped $500 billion,3 
and the global market is predicted to exceed $1.5 trillion annually by 2023.4 “About 
46 percent of the U.S. population used one or more prescription drugs in the past 30 
days.”5 While this is a sizeable portion of the population, even more Americans are 
purchasing over-the-counter (OTC) medicines.6 On average, United States 
consumers make twenty-six trips a year to purchase OTC products, and United 
States households spend about $338 per year on OTC medicines.7 When going to a 
store, doctor’s office, or pharmacy, a consumer wants to be able to trust that the 
medicine they are receiving is the medicine they intend to take. This intention can 
lead consumers to choose trusted brand names over generic products, even though 
the generic is normally the cheaper option.8 
 
1  Entry From April 26, 2015, BARRY POPIK (Apr. 26, 2015), 
https://www.barrypopik.com/index.php/new_york_city/entry/it_rains_on_rich_and_poor_alike. 
2  Bryan A. Liang, A Dose of Reality: Promoting Access to Pharmaceuticals, 8 WAKE FOREST INTELL. PROP. L.J. 
301, 301 (2007). 
3  Eric M. Tichy, James M. Hoffman, Katie J. Suda, Matthew H. Rim, Mina Tadrous, JoAnn Stubbings, 
Sandra Cuellar, John S. Clark, Michelle D. Wiest, Linda M. Matusiak, Robert J. Hunkler, & Lee C. 
Vermeulen, National Trends in Prescription Drug Expenditures and Projections for 2020, AM. J. HEALTH 
SYS. PHARMACISTS, 1213, 1214 (2020). 
4  The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA INST. (Jan. 29, 2019), 
https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-
to-2023. 
5  Shelly Hagan, Nearly One in Two Americans Takes Prescription Drugs: Survey, BLOOMBERG (May 8, 2019), 
https://www.bloomberg.com/news/articles/2019-05-08/nearly-one-in-two-americans-takes-prescription-
drugs-survey (citing a 2015–2016 survey from the National Center for Health Statistics). 
6  See Statistics on OTC Use, CONSUMER HEALTHCARE PRODS ASS’N, https://www.chpa.org/about-consumer-
healthcare/research-data/otc-use-statistics (last visited Nov. 19, 2019). 
7  Id.  
8  See Lauren Friedman, Here's Why You Should Always Buy Generic Drugs, BUS. INSIDER (May 6, 2014), 
https://www.businessinsider.com/generic-drugs-vs-brand-name-2014-5 (explaining the problems with the 
negative perception of generic medicine and how this hurts the consumer); see also Keri Sewell, Susan 
Andreae, Elizabeth Luke, & Monika M. Safford, Perceptions of and Barriers to Use of Generic Medications 
in a Rural African American Population, Alabama, 2011, CTRS. FOR DISEASE CONTROL (Aug. 30, 2012), 
https://www.cdc.gov/pcd/issues/2012/12_0010.htm (explaining how previous studies show that 
disadvantaged people, who may particularly benefit from cost savings, have low trust of generics and 
increased reluctance to switch to generics). 
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Despite their attempts to get the best and most trusted drugs, consumers’ 
efforts can still be thwarted, and people can end up receiving fake medicines. 
Counterfeit goods, such as copies of luxury clothing or accessories, only mislead the 
customer but result in no actual harm, unlike the possible effects of taking a fake 
pharmaceutical.9 The growing counterfeit drug market has vast implications on 
both personal and public health for people across the globe,10 so much so that it has 
been “regarded as murder or terrorism and the greatest evil against human health 
and economy.”11 
The issues surrounding counterfeit drugs have been written about 
extensively, and papers commonly explore the inadequacies in current laws, 
enforcement of those laws, and penalties for counterfeiters.12 Understanding these 
three aspects is important for the supply side of this issue, but the demand side is 
tantamount in importance as consumer need is “the root of the problem,” and 
consumers are ultimately the ones receiving the counterfeit products.13 Consumers 
have the power to decide what to purchase but will purchase what they can afford 
and what they trust. To ensure the medicines sold to customers are legitimate, 
governments and companies need to strengthen regulations and enforce intellectual 
property rights—specifically trademarks—while balancing this increased protection 
with reasonable prices that consumers will actually be able to afford. 
This Note will explore the history and current state of the counterfeit drug 
crisis within developing countries as compared to the United States. This drug crisis 
is truly a global issue and not isolated to one country. As supply chains get more 
complicated with international production and shipping, there is a higher likelihood 
that counterfeit goods will enter the global supply chain and ultimately reach the 
consumer. Part I explains the nuances of the problem in different regions across the 
globe and shows that certain populations, such as women, children, and the elderly, 
are more likely to be affected by counterfeit drugs. Part II examines previous 
attempts, both within specific regions and internationally, to ameliorate the 
situation by using treaties and intellectual property protection. Part III explores 
trademark protection within the pharmaceutical industry, why this is the type of 
intellectual property we should be focusing on with this issue, and how stronger 




9  Sandra L. Rierson, Pharmaceutical Counterfeiting and the Puzzle of Remedies, 8 WAKE FOREST INTELL. 
PROP. L.J. 433, 434–35 (2007). 
10  Joel Breman, It’s Time to Stop Murder by Counterfeit Medicine, STAT (May 7, 2019), 
https://www.statnews.com/2019/05/07/stopping-murder-counterfeit-medicine. 
11  Linus Mhando, Mary B. Jande, Anthony Liwa, Stanley Mwita, & Karol J. Marwa, Public Awareness and 
Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs, 2016 ADVANCES PUB. 
HEALTH 1, 2. 
12  Robert C. Bird, Counterfeit Drugs: A Global Consumer Perspective, 8 WAKE FOREST INTELL. PROP. L.J. 387, 
388 (2007). 
13  Id. (explaining “how the supply side of fake drugs can be curtailed through a combination of governmental 
and industry actions.”). 
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I. THE COUNTERFEIT DRUG PROBLEM 
 
A. Defining the Problem 
 
The issue of counterfeit drugs is not new to society; there are references to 
supplies of fake antimalarial medicines with fake cinchona bark in the early 1600s, 
and more recently, counterfeit quinine in the 1800s.14 Today, the presence of fake 
medicine, in general, is an increasingly tenacious public health issue across the 
globe.15 Because this is a global issue and affects different regions and countries in 
various ways to varying degrees, there has not been an international consensus on 
the definition of a counterfeit drug.16 The scope and definition of the counterfeit 
drug crisis have evolved over the last few decades as the issue has become more 
prevalent and well-known. The World Health Organization (WHO) previously 
defined a counterfeit drug as a medicine that is “deliberately and fraudulently 
mislabelled with respect to identity and/or source.”17 This definition has evolved as 
the WHO tried to simplify it by creating three categories of harmful drugs: (1) 
“falsified medical products deliberately misrepresent their identity and are 
distributed with criminal intent”; (2) “substandard medical products fail to meet 
quality standards”; and (3) “unregistered or unlicensed medical products have not 
been assessed or approved.”18 Each of these categories comes with ways that harm 
could potentially manifest for the consumer; the counterfeit drugs could not only 
waste their money but can also have serious implications to their health.19 
The first category, which covers falsified medical products, is the focus here. 
For this first category, the patient will not be treated for their disease or condition 
as the medicine will often be a different type of drug or a placebo with no active 
ingredient.20 Some studies estimate that “up to 76 percent of the counterfeit drugs 
on the [global] market contain either no active ingredient or incorrect ingredients, 
with 10 to 15 percent containing [some type of] contaminants.”21 Those that simply 
lack an active ingredient but are not contaminated might not directly harm the 
 
14  Paul N. Newton, Michael D. Green, & Facundo M. Fernández, Impact of Poor-Quality Medicines in the 
‘Developing’ World, 31 TRENDS PHARMACOLOGICAL SCI. 99, 99 (2010). 
15  Amanda Chaves, A Growing Headache: The Prevalence of International Counterfeit Pharmaceutical Trade 
in Developing African Nations, 32 SUFFOLK TRANSNAT’L L. REV. 631, 633 (2009). 
16  Victoria Rees, The Impact of Counterfeit Drugs in South and South-East Asia, EUR. PHARMACEUTICAL REV. 
(July 3, 2019), https://www.europeanpharmaceuticalreview.com/article/92194/the-impact-of-counterfeit-
drugs-in-south-and-south-east-asia/. 
17  Id. 
18  Breman, supra note 10. 
19  Erwin A. Blackstone, Joseph P. Fuhr, Jr., & Steve Pociask, The Health and Economic Effects of Counterfeit 
Drugs, 7 AM. HEALTH & DRUG BENEFITS 216, 221 (2014). 
20  Liang, supra note 2, at 305–06; see Rick Roberts, Counterfeit Biologics: A Personal Narrative, 10 J. BIOLAW 
& BUS. 37, 38 (2007) (describing fake growth hormone substituted with human chorionic gonadotropin, a 
female steroid); see also Blackstone et al., supra note 19. 
21  Amy M. Bunker, Deadly Dose: Counterfeit Pharmaceuticals, Intellectual Property and Human Health, 89 J. 
PAT. & TRADEMARK OFF. SOC’Y 493, 496 (2007). 
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patient, but taking these drugs can result in the patient failing to be treated and 
could lead to future health implications, such as resistance to antibiotics.22  
Other situations are much more perilous as they can introduce dangerous 
substances to the body that could lead to death or serious injury. Manufacturers of 
these illegal drugs are concerned with maximizing profits and generally disregard 
the safety of the medicine they are making, which can lead to drugs being made 
from a wide variety of toxic or poisonous materials.23 Some examples of these 
harmful ingredients include “bacteria-laced water, toxic yellow paint, floor wax, 
colored dye, powdered cement, boric acid, and antifreeze.”24 One specific example 
was a counterfeit case of the blood thinner heparin that caused as many as eighty-
one deaths and resulted in a nationwide recall after it was discovered that the 
active ingredient was replaced with a cheaper substance that originated in China.25 
Other times, the manufacturer may use the right drug, but it either uses less 
of the drug to save money or makes it incorrectly for a variety of reasons, which 
leads to the wrong concentration or dose of the drug. 26 This can also lead to death 
or cause severe complications for patients.27 Finally, the fake medicine might not 
contain the wrong dose or contaminants, but it might just be the wrong drug 
altogether.28 For example, the weight-loss medication Alli has been counterfeited 
with a fake version that contains the controlled substance sibutramine instead of 
orlistat; and the Food and Drug Administration (FDA) reported that this substance 
could produce harmful interactions with other medications a patient may be 
taking.29 
The types of counterfeit drugs have also shifted throughout the decades and 
now span a wider variety—ranging from “lifestyle drugs to lifesaving drugs.”30 
Early on, the focus was on lifestyle drugs for things such as “diet, erectile 
dysfunction, and hair growth pills.”31 Detection has since shifted to more serious 
lifesaving drugs including “anti-arthritis drugs, antibiotics, antihistamines, anti-
 
22  Blackstone et al., supra note 19, at 218. A doctor may end up prescribing stronger antibiotics if they believe 
the original prescription was not working, when in reality, the patient could have never received any actual 
antibiotics. See also Ben Hirschler, Tens of Thousands Dying from $30 Billion Fake Drugs Trade, WHO 
Says, REUTERS (Nov. 28, 2017) https://www.reuters.com/article/us-pharmaceuticals-fakes/tens-of-thousands-
dying-from-30-billion-fake-drugs-trade-who-says-idUSKBN1DS1XJ. 
23  Bunker, supra note 21, at 496–97. 
24  Blackstone et al., supra note 19, at 218 (explaining how children died after taking acetaminophen syrup to 
remedy a cough but the medicine had been made with glycerol contaminated with ethylene glycol, an 
ingredient in antifreeze). 
25  Id.  
26  Id. 
27  Id. (“One example of this is the case of a physician who was supplied with a research version of 
onabotulinumtoxinA (Botox) that was much more concentrated than the real medicine, and is not intended 
for human use. This resulted in respiratory paralysis and near death for several patients, including the 
physician who was using it himself.”). 
28  Id.  
29  Id.  
30  Liang, supra note 2, at 305.  
31  Id.; Jessica McLaughlin, The United States Isn’t Immune to Counterfeit Drugs, LAW STREET (May 8, 2015), 
https://www.lawstreetmedia.com/issues/health-science/united-states-isnt-immune-to-counterfeit-drugs/.  
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parasitic drugs, AIDS/HIV therapy, cancer drugs, cardiac drugs, cholesterol drugs, 
flu medications, hormone replacement therapy, insulin, over-the-counter pain 
medications, and many more.”32 For example, in 2012, the FDA discovered that two 
lots of an imported cancer medicine were counterfeit and contained none of the 
active ingredient and instead contained salt and starch.33 This shift is important to 
note as it affects people with life-threatening diseases.34 If a person takes a placebo 
diet pill, they have most likely just wasted their money and will not get any help 
losing weight from the pill; however, if a doctor administers antimalarial medicine 
to a patient that turns out to be fake, the patient could die from not receiving the 
medicine they needed. Additionally, this issue extends beyond just medicine and 
impacts a variety of health-related products. For example Homeland Security 
Investigations agents recently removed over 300 counterfeit contact lenses from a 
store in Texas.35 This is particularly concerning as sixty percent of counterfeit 
lenses tested positive for microbial contamination, which could lead to serious 
infections, or even blindness, due to diseases such as microbial keratitis and 
bacterial endophthalmitis.36 
 
B. The Counterfeit Drug Market 
 
The market for counterfeit drugs is neither new nor insignificant—it has 
matured, expanded, and shifted. This expansion was spurred by the rapid growth of 
the pharmaceutical market in general.37 The industry that is now worth $1.2 
trillion38 has grown incredibly quickly in the past few decades. Likewise, the growth 
of the counterfeit market has paralleled the rapid growth of the pharmaceutical 
 
32  Liang, supra note 2, at 305; see also Bunker, supra note 21, at 496 (“In 2003, for example, the WHO stated 
that half of the reported cases of counterfeit drugs involved antibiotics.”). 
33  Eric Palmer, Feds Nail Key Player in Counterfeit Avastin Probe, FIERCEPHARMA (Apr. 24, 2013, 9:09 AM), 
www.fiercepharma.com/story/feds-nail-key-player-counterfeit-avastin-probe/2013-04-24. 
34  See, e.g., Charles Bennett, Government Agencies and Pharmaceutical Industry Must Take Action to Thwart 
Sales of Counterfeit Drug Products, CANCER NETWORK, (Sept. 1, 2006), 
https://www.cancernetwork.com/articles/government-agencies-and-pharmaceutical-industry-must-take-
action-thwart-sales-counterfeit-drug (explaining a situation where a patient was being treated for anemia 
following a liver treatment and received eight weeks of counterfeit medicine instead of the lifesaving 
medicine he needed); see also 1 in 10 Medical Products in Developing Countries is Substandard or Falsified, 
WORLD HEALTH ORG., (Nov. 28, 2017), https://www.who.int/news-room/detail/28-11-2017-1-in-10-medical-
products-in-developing-countries-is-substandard-or-falsified (“Since 2013, the WHO has received 1500 
reports of substandard or falsified products.” The most frequently reported products were antimalarial 
medicines and antibiotics). 
35  Busted: Feds Seize Hundreds of Illegal, Counterfeit Contact Lenses, AM. OPTOMETRIC ASS’N (Oct. 31, 2019), 
https://www.aoa.org/news/advocacy/homeland-security-agents-bust-counterfeit-contact-lens-dealers.  
36  Id. 
37  See Bunker, supra note 21, at 494. 
38  Global Pharma Spending Will Hit $1.5 Trillion in 2023, Says IQVIA, PHARMACEUTICAL COM. (Jan. 29, 
2019), https://pharmaceuticalcommerce.com/business-and-finance/global-pharma-spending-will-hit-1-5-
trillion-in-2023-says-iqvia/ (referencing the Global Use of Medicines report from the IQVIA Institute for 
Human Data Science). 
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industry.39 “The National Association of Boards of Pharmacy estimated that 
counterfeit drugs generated $75 billion in revenues in 2010,”40 with estimates of it 
now being worth around $200 billion, making the counterfeit pharmaceutical 
market almost as valuable as the illicit drug trade.41 Further, this rapid growth is 
not predicted to stop, but is predicted “to grow by twenty percent annually” and is 
currently “growing at twice the rate of legitimate pharmaceuticals.”42 
The size of the counterfeit market is exacerbated by the following: the high 
price of name brand pharmaceuticals, the shortages of important drugs, the rise of 
online pharmacies, convoluted supply chains, low penalties for those who are caught 
selling counterfeit drugs, and the low cost of manufacturing the fake medicines. 
There is a relationship between products associated with high prices, such as luxury 
goods, pharmaceuticals, and copyrighted media, and consumer demand for 
counterfeit products.43 Part of the reason for the high costs of pharmaceutical drugs, 
especially those without a generic version, are the intellectual property rights that 
the companies maintain on the medicines, primarily patents and their associated 
monopoly pricing.44 For the limited term of the patent, the company can price the 
drug at higher prices as there are no other companies selling the drug or a generic 
version.45 The drugs need to be priced higher to recoup the costs of drug 
development—twenty percent of drugs approved by the FDA generate seventy 
percent of the returns for pharmaceutical companies.46 This demand for counterfeit 
medicines created by high drug prices is further increased when crucial drugs are in 
short supply as consumers may be more desperate for the medicine.47 Consumers 
will either have to pay the high price for the drug if they can access it or search 
beyond their normal markets for a cheaper source, such as an online pharmacy, 
which increases the chance they will receive a counterfeit. 48  
 
39  See Kim Overstreet, $200 Billion Pharma Counterfeit Drug Market Growing by 20% Per Year, PACKAGING 
WORLD (Nov. 26, 2019), https://www.packworld.com/home/article/21102806/200-billion-pharma-counterfeit-
drug-market-growing-by-20-per-year (“This alarming growth is twice the rate of the legitimate 
pharmaceutical market, and accounts for 2.5% of the total global pharma market.”).  
40  Blackstone et al., supra note 19, at 219. 
41  Kristina Acri, They Cost Us Billions and They Can Kill: Counterfeit Drugs are Invading Canada, FIN. POST 
(Mar. 2, 2018), https://business.financialpost.com/opinion/they-cost-us-billions-and-they-can-kill-counterfeit-
drugs-are-invading-canada (noting that the illicit drug trade was worth $246 billion in 2013).  
42  Id.  
43  Susan K. Sell, TRIPs Was Never Enough: Vertical Forum Shifting, FTAS, ACTA, and TPP, 18 J. INTELL. 
PROP. L. 447, 459–60 (2011). 
44  Liang, supra note 2, at 322.  
45  See id. at 103, 322.  
46  Id. at 322–23. 
47  Blackstone et al., supra note 19, at 221; see also Hannah Balfour, Chinese Police Seize Over 3,000 Fake 
COVID-19 Vaccines, EUR. PHARMACEUTICAL REV. (Feb. 8, 2021), 
https://www.europeanpharmaceuticalreview.com/news/142118/chinese-police-seize-over-3000-fake-covid-19-
vaccines/ (explaining how manufactures of counterfeit COVID-19 vaccines are exploiting people who are 
desperate to receive the in-demand vaccine). 
48  Blackstone et al., supra note 19, at 221; see also Louisa Wright, Officials Warn of Fake COVID-19 Vaccines, 
DEUTSCHE WELLE (Jan. 4, 2021), https://www.dw.com/en/officials-warn-of-fake-covid-19-vaccines/a-56123830 
(explaining how fake vaccines for COVID-19 are being sold online which is dangerous and the large demand 
for the vaccine is triggering criminal activity).  
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Those who are manufacturing fake drugs are the only winners in this story. 
Consumers are ripped off or injured, drug companies lose profits, and drug 
development and research are stifled. The culprits do not have to meet the quality 
standards of normal, legitimate drug manufacturers, market their product, worry 
about securing intellectual property rights, engage in years of costly research, or 
partake in any of the other expensive and time-intensive steps that a real drug 
company goes through to get their product on the market.49 They can “free-ride” off 
of an established brand and make the fake product for twenty percent of what it 
costs legal manufacturers.50 They can use whatever ingredients they have on hand 
and make a significant return on investment without needing much skill.51 
Furthermore, this market is so profitable and successful that it is “more lucrative 
than the narcotics business because counterfeit drugs are worth more than illicit 
drugs.”52 One expert estimates that investors can earn up to thirty times their 
investment on prescription drugs, which is a staggering ten times the profit rate of 
trafficking heroin.53 Coupled with the possibility of these large profit margins is a 
small chance of facing prosecution.54 While each country has its punishments, it is 
difficult for the United States to prosecute foreign nationals for this crime.55 
The counterfeit drug market also has implications on legitimate 
pharmaceutical companies and can deprive society of potential future drugs. It goes 
beyond just lost revenue for these companies. They are forced to spend their money 
monitoring their supply chain, investing in anti-counterfeiting technologies, trying 
to repair their reputations, and dealing with liability risks.56 Counterfeit drugs can 
also lead to lawsuits for pharmaceutical companies. For example, in the heparin 
case discussed earlier, the company that sold the drug was subject to over 700 
lawsuits as a result of the counterfeit ingredients causing deaths for consumers.57 
With more money being spent trying to fix these issues, there are fewer resources 
for research and development of future drugs.58 With less investment in research, 
there are fewer discoveries and new medicines for diseases, causing many people 
around the world to suffer or die at the hands of these copycat drug 
 
49  Bird, supra note 12, at 393–94 (citing Natasha Wong, Counterfeit Medicine: Is it Curing China?, 5 ASIAN-
PAC. L. & POL’Y J. 155, 171 (2004) (“[The counterfeit pharmaceutical distributor] will make a substantial 
profit based upon his non-existent research and development, lack of advertising costs, and dependence 
upon the public’s trust of the name brand’s product reputation, which he is taking advantage of with 
counterfeit goods.”).  
50  Id. 
51  Bunker, supra note 21, at 507. 
52  Acri, supra note 41.  
53  See Blackstone et al., supra note 19, at 220; see also Rachel Ehrenberg, Counterfeit Crackdown, SCI. NEWS 
(June 3, 2011, 10:50 AM), https://www.sciencenews.org/article/counterfeit-crackdown. 
54  Bunker, supra note 21, at 507. 
55  Counterfeit Medicine in America: 2018, PARTNERSHIP FOR SAFE MEDS. (Oct. 29, 2018), 
https://www.in.gov/bitterpill/files/Safdar-Counterfeit-IN-AG-Opioid-Summit-2018-10-29-FINAL.pdf.  
56  Acri, supra note 41. 
57  Blackstone et al., supra note 19, at 217.  
58  Acri, supra note 41. 
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manufacturers.59 Drugs are already very expensive to develop—a new prescription 
medicine is estimated to cost the drug maker around $2.6 billion.60 If drugs are this 
expensive to develop and companies are worried their work will just be 
counterfeited, there is even less incentive for companies to invest in producing new 
drugs. 61 
 
C. Counterfeit Drugs in the United States 
 
The United States is not immune to the effects of fake medicines, even 
though it has the safest drug supply in the world.62 The United States has managed 
to do a good job protecting its consumers from fake drugs through “combined efforts 
of the U.S. government, the U.S. pharmaceutical industry, and local authorities 
world-wide” that disrupt the counterfeit drug operations.63 Despite these efforts, 
however, some counterfeit drugs still manage to make it into the country, and 
Americans are largely unaware of the threat these medicines pose to their society.64 
One study showed that a mere twelve percent of Americans feel they have enough 
information on counterfeit medicines, and in most cases, are more likely to associate 
counterfeiting with consumer goods rather than medicines.65 Each year as many as 
nineteen million people in the United States purchase medicine outside the normal 
manufacturer-to-supplier direct supply chain and use online pharmacies or other 
unconventional sources instead.66 Ten percent of drugs distributed each year are 
not distributed by national wholesalers to the end supplier, such as the pharmacy or 
hospital.67 This is where the issues arise. The domestic drug supply has been 
relatively immune to the counterfeit issue, but the fake drugs managed to make it 
into the hands of American citizens through numerous breaks in the supply chain, 
with many of the drugs having international origins.68 A recent report showed that 
nearly forty percent of drugs in the United States are manufactured overseas, and 
around eighty percent of the active ingredients for the drugs manufactured on 
American soil are imported from abroad.69 
 
59  Bunker, supra note 21, at 494, 515. 
60  Thomas Sullivan, A Tough Road: Cost to Develop One New Drug is $2.6 Billion; Approval Rate for Drugs 
Entering Clinical Development is Less Than 12%, POL’Y & MED. (Mar. 21, 2019), 
https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-
for-drugs-entering-clinical-de.html.  
61  Bunker, supra note 21, at 494. 
62  Counterfeit Medicine in America: 2018, supra note 55. 
63  Bunker, supra note 21 at 506. 
64  Counterfeit Medicine in America: 2018, supra note 55. 
65  Perceptions of Counterfeit Medicines: Only 12% of Americans Feel They Have Enough Information, SANOFI 
(Nov. 20, 2015), http://www.multivu.com/players/English/7697951-sanofi-counterfeit-medicines. 
66  Counterfeit Medicine in America: 2018, supra note 55. 
67  Blackstone et al., supra note 19, at 218. 
68  Liang, supra note 2, at 309. 
69  Memorandum from the U.S. House of Representatives, Comm. on Energy & Commerce., Majority Comm. 
Staff to Members, Subcomm. on Oversight and Investigations. (Feb. 25, 2014) (on file with the House of 
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As the supply chain grows, so does the chance of counterfeits being 
introduced into the chain. The drug Epogen, for example, caused extreme health 
issues for a patient who just underwent a liver transplant; it had a convoluted 
supply chain that included at least thirteen chains of ownership and was handled 
by the manufacturer, the major distributor, “3 different wholesalers, 2 pharmacies, 
4 unlicensed go-betweens, and 1 suspected counterfeiter.”70 While this specific drug 
was purchased from a pharmacy, there are times when consumers will turn to 
sources beyond the norm for their drugs, specifically when there are drug 
shortages.71 The complex supply chains and drug shortages exacerbate this issue. In 
short, “[s]hortages of key medicines in the US and Europe have created new 
opportunities for illicit traders, while ever-longer manufacturer supply chains open 
the door to diversion and theft.”72  
One example of people going beyond the normal market is when United 
States citizens ignore federal law and cross the border to purchase drugs from 
Canada or Mexico, or alternatively, purchase drugs online.73 Discussed later, Asian 
countries are the biggest culprits in the production of fake drugs,74 but Mexico is a 
threat due to its proximity to the United States and an abundance of fake drugs.75 
While this should be concerning for Mexican citizens, it also affects Americans who 
decide to purchase drugs while abroad due to the high cost or shortage in their 
home country. This market is significant in size as one estimate approximated that 
Americans spend upwards of $800 million a year on pharmaceuticals from Mexico.76 
The issues from Canada come less from actually crossing the border and 
instead present themselves in the form of online pharmacies, which have been on 
the rise with approximately 35,000 of them appearing over the last decade.77 The 
FDA estimates that about twenty-five percent of internet users have purchased 
medicine online.78 Overall, Americans are not aware of the dangers they face when 
purchasing drugs from these pharmacies and do not realize they could be receiving 
fake medicine.79 These websites will pretend to be Canadian pharmacies, but this is 
 
Representatives Document Repository, http://docs.house.gov/meetings/IF/IF02/20140227/101804/HHRG-
113-IF02-20140227-SD002.pdf). 
70  Blackstone et al., supra note 19, at 218. 
71  See id. at 218–19. 
72  Id. (quoting Jill Wechsler, Campaign Mounts to Curb Counterfeit Drugs, 25 BIOPHARM INT’L 40 (2012)). 
73  Bernard Wolfson, Here’s What Can Go Wrong When You Shop in Mexico and Canada for Cheap Drugs, L.A. 
TIMES (Aug. 19, 2019, 12:05 PM), https://www.latimes.com/business/story/2019-08-19/shop-mexico-canada-
cheap-drugs. 
74  See infra Part I.D. 
75  See, e.g., DEA Issues Warning Over Counterfeit Prescription Pills from Mexico, U.S. DRUG ENFORCEMENT 
ADMIN. (Nov. 4, 2019), https://www.dea.gov/press-releases/2019/11/04/dea-issues-warning-over-counterfeit-
prescription-pills-mexico-0 (warning Americans of the dangers of counterfeit drugs from Mexico and 
explaining how twenty-seven percent of the drugs sampled contained potentially lethal doses of fentanyl). 
76  Marv Shepherd, Drug Quality, Safety Issues and Threats of Drug Importation, 36 CAL. W. INT’L L.J. 77, 80 
(2005). 
77  Breman, supra note 10. 
78  Blackstone et al., supra note 19, at 219. 
79  Id. 
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often a hoax; less than two percent “claiming to be Canadian were actually 
registered in Canada,” while the remaining were actually registered to other 
countries across the world.80 Customers turn to these websites to save money and 
are attracted to claims boasting savings up to seventy-five percent, but they are 
potentially losing and wasting money on medication that will, at best, do nothing for 
them and, at worst, kill them.81 Further, eighty-eight percent of the “most 
commonly prescribed generic drugs can be purchased more cheaply in the U.S. than 
from Canadian pharmacies.”82 Beyond the economic and personal health threats 
these websites pose, it has been found that some of them are actually “linked to 
terrorist groups, such as Hezbollah and Al Qaeda, and others are linked to 
organized crime––posing a threat to national and international security.”83 
Once again, the power here lies in the consumer and their beliefs. American 
consumers often do not see the dangers that come with shopping online for medicine 
or the re-importation of drugs from Canada.84 If the possibility of receiving fake 
medicine from Canada is worth the risk, the consumer should first check cipa.com, a 
website run by the Canadian International Pharmacy Association, to check if the 
seller’s website is legitimate.85 While it is still currently illegal to get drugs this 
way, the Trump administration considered opening up drug importation from 
Canada.86 This would have allowed states to import medicine from Canada but is 
not guaranteed to get consumers cheaper or safer drugs.87 This would have 
implications on the supply stream, which, as previously discussed, is already 
susceptible to being comprised and infiltrated with counterfeit drugs. Overall, the 
United States is not immune to the effect of counterfeit drugs, but the high prices 
forced on its consumers cause them to seek potentially dangerous sources for their 
medicine. 
 
D. The Problem is Intensified in Developing Countries  
 
“According to the WHO, 1 in 10 medical products in developing countries is 
falsified or substandard.”88 Some argue that this exact percentage and the true 
 
80  Id. 
81  Id. at 220 (“Tap water or bacteria at a discount of 75% off the price of the legitimate drug is no bargain for 
anyone.”). 
82  Wolfson, supra note 73. 
83  Blackstone et al., supra note 19, at 220.  
84  Id. at 219. 
85  Wolfson, supra note 73.  
86  Id. (“Despite the official prohibition, FDA guidelines allow federal agents to refrain from enforcement ‘when 
the quantity and purpose are clearly for personal use, and the product does not present an unreasonable 
risk to the user.’”); Noam Levey, Trump Administration to Consider Plans to Import Prescription Drugs 
from Canada, L.A. TIMES (July 31, 2019), https://www.latimes.com/politics/story/2019-07-31/trump-
administration-drugs-canada.  
87  Levey, supra note 86. 
88  Breman, supra note 10; WORLD HEALTH ORG., supra note 34 (explaining an analysis of 100 studies from 
2007 to 2016, covering more than 48,000 samples, that showed 10.5 percent of drugs in low and middle-
income countries to be fake or substandard). 
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impact on the pharmaceutical market is hard to establish on a country and global 
scale, but the numbers consistently indicate that developing countries are the most 
affected by the counterfeit drug problem. 89 For example, in Africa and parts of Asia, 
up to sixty percent of the drugs could be counterfeit.90 Counterfeit rates of drugs in 
these countries are high for several reasons. First, developing countries often do not 
have the money or resources to (1) monitor and regulate the supply chain and (2) 
test to see if the medicine is authentic.91 “Expensive analytic equipment generally 
isn’t available, while simple, accurate, and inexpensive testing systems for use in 
the field, at pharmacies, and at the point of care remain out of reach in virtually all 
poor countries.”92 Second, the laws, enforcement of regulations, and judicial actions 
for identified criminals are poorly defined.93 Sometimes the proper officials are in 
place, but corruption leads to them being bypassed and allows counterfeits to slip 
through.94 Consumers play a role, as they often lack knowledge about fake drugs 
and often need drugs that are in short supply.95 Finally, these countries not only 
lack the needed laws and resources to tackle this issue, but they are also busy 
handling other crimes. For example, in one survey, counterfeiting was connected to 
organized crime nearly thirty percent of the time and drug crimes forty percent of 
the time. 96 The two areas of the world most affected by this are parts of Asia and 
Africa, with sales of fake medicines amounting to $5 billion per year.97 These 
regions are the perfect target for counterfeiters, as up to sixty percent of essential 
medicines are not available to the people there, causing the drugs to be in extremely 
high demand.98 The rest of this section will examine these regions and how their 
mostly poor populations must deal with major public health crises in very prevalent 
and growing counterfeit drug markets.99 
There are more detected cases of counterfeit drugs in Africa than in any other 
region of the world.100 Along with the reasons mentioned above, these counterfeit 
 
89  Bunker, supra note 21, at 497. 
90  Mhando et al., supra note 11.  
91  See Breman, supra note 10. 
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93  Id.  
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96  The Illicit Trafficking of Counterfeit Goods and Transnational Organized Crime, UNITED NATIONS OFF. ON 
DRUGS & CRIME, 
https://www.unodc.org/documents/counterfeit/FocusSheet/Counterfeit_focussheet_EN_HIRES.pdf. 
(“Evidence suggests that criminal networks use similar routes and modus operandi to move counterfeit 
goods as they do to smuggle drugs, firearms and people.”). 
97  Id.  
 98 See Sheila Mysorekar, Silent Murder, DEV. & COOPERATION (Mar. 14, 2013), 
https://www.dandc.eu/en/article/medicines-are-too-expensive-poor-people-developing-countries-local-
production-could-make. 
99  Bunker, supra note 21, at 499. 
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drugs are especially prevalent in Africa due to the desire for affordable medicine, so 
much so that even some pharmacists admit to purchasing medicine from the 
cheapest, but not always the safest, drug suppliers.101 Furthermore, many African 
nations are led by corrupt governments that either fail to regulate the counterfeit 
market or sympathize with small business owners even if they are “engaging in the 
counterfeit drug trade.”102 The types of drugs counterfeited in Africa are most 
commonly crucial, life-saving drugs for diseases such as malaria.103 For every one 
million people who die from malaria, up to forty-five percent of the deaths were 
affected by counterfeit medicine.104 One WHO report estimated that “at least 72,000 
children die of pneumonia and 69,000 people die of malaria each year as a result of 
falsified or substandard treatments.”105 While counterfeit drugs have been an issue 
in Africa for decades, the issue is not likely to go away anytime soon, especially due 
to the incredible growth rate of the continent’s pharmaceutical market.106 It was 
predicted that the market would triple and reach $65 billion by 2020.107 As Africa 
becomes more popular for pharmaceutical companies, it will begin to attract 
additional counterfeiters.108 
Currently, Africa’s problems with counterfeits are unlikely to go away unless 
they are cut off at the source—Asia. The problem is so severe that in just two weeks, 
the World Customs Organization (WCO) stopped over 100 million counterfeit drugs, 
which is “just a drop in the ocean,” from entering Africa from Asian 
manufacturers.109 Asia is less directly impacted by being infiltrated with counterfeit 
drugs, but rather, is the biggest culprit in the production of the medicines, with 
ninety-seven percent coming from China or India.110 As mentioned before, it is hard 
to get exact statistics on this issue, so it is difficult to say which country is the 
biggest culprit. One study found that up to three out of every four counterfeit drugs 
originate in India,111 while others believe that China is the largest producer of these 
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https://www.euractiv.com/section/health-consumers/news/counterfeit-chinese-and-indian-drugs-invade-
africa/. 
110  Id. 
111  Mhando et al., supra note 11. 
2021] Trademark Enforcement of Counterfeit Drugs 293 
 
drugs.112 Other smaller countries “such as Myanmar, Cambodia, Indonesia, and 
Thailand are beginning to manufacture fake pharmaceuticals.”113 While these 
countries are less likely to produce the pharmaceuticals (only two percent of the 
drugs come from Southeast Asia),114 they play a significant role in the transport of 
the drugs as major transit points in the process. There are three main reasons why 
these countries are ideal for transporting fake pharmaceuticals: (1) the countries 
are all well connected physically; (2) free-trade agreements ease transport without 
legal barriers;115 and (3) many of these countries have major ports, which is 
convenient as “50-60 percent of illicit traffic is shipped via sea.”116 
 
E. At-Risk Populations Affected by This Crisis 
 
“[R]esearch findings clearly show that the poorest and most vulnerable 
populations suffer the most.”117 The elderly, children, women, and the poor have all 
faced serious consequences from fake medicine. While developing countries, as just 
discussed, are more likely to be affected, those with less money in any country are 
at a greater risk of being exposed to counterfeit drugs. While the affluent could still 
receive a fake drug that sneaks its way into the supply stream, they are less likely 
to stray from the normal sources to get their medicines.118 Those with less money 
may feel like they have no option other than to go online, or even to another 
country, to get their medicine at an affordable price.119 This is frequently seen with 
senior citizens in America who go on trips to Mexico to buy prescription drugs.120 
Children are also frequently the victims of this crime. Children cannot control the 
medicine they are given, are not informed about these problems, and do not choose 
where their medicine comes from. One horrifying example of this was when “[m]ore 
than 500 children around the world died from counterfeit cough syrup that was 
tainted with ethylene glycol,” commonly known as antifreeze.121 Another tragic case 
involved inhalers that were contaminated with bacteria and used to treat children 
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with cystic fibrosis (CF),122 a disease that can cause fast lung function decline when 
someone with CF is exposed to bacteria.123 
Finally, women are also susceptible to the detriments of counterfeit drugs 
when taking birth control medications. Access to pharmaceutical contraceptives is 
still a challenge for some women. Even in the United States, close to twenty million 
women either live in a contraceptive dessert or need publicly funded 
contraception.124 Further, the United States is one of forty-five countries that 
requires a prescription to get the birth control pill.125 When drugs are difficult to 
get, people turn to online pharmacies, which is where counterfeit drugs are most 
likely to become a problem. There are two prominent examples of counterfeit birth 
control: (1) “in 1998, Brazil reported approximately 200 unwanted pregnancies from 
the use of counterfeit contraceptive pills”;126 and (2) in 2004 there was an FDA 
warning about online pharmacies selling contraceptive patches containing no active 
ingredient, which could then lead to unplanned pregnancy.127 So, while this is a 
global issue that has implications for everyone, some groups of people are more 
likely to impacted by this crime. 
 
II. POSSIBLE REMEDIES 
 
Counterfeit goods are not new, and neither are attempts to stop them from 
being sold. Other types of products mostly impact the manufacturer and do not put 
the consumer in danger as counterfeit pharmaceuticals do.128 Not only is this 
problem dangerous, but it is also extremely costly to pharmaceutical companies. 
There are major incentives for both the governments of impacted countries and 
pharmaceutical companies to try to stop these drugs from reaching the consumers. 
Pharmaceutical companies have recognized the significance of this problem and 
have started their own ways of intervening, given that decades of government and 
international attempts to remedy the problem have not been enough to stop the 
problem. For example, Pfizer has a global security team to battle counterfeiters.129 
Also, Eli Lilly has invested over $100 million in combatting fake drugs by creating 
traceable stamping codes for each of its products, allowing them to trace the drug 
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from being manufactured to finally reaching the patient.130 While pharmaceutical 
companies stepping in can improve safety for consumers, it causes them to spend 
their money on these measures instead of research or lowering prices for customers. 
 
A. Attempts by Individual Regions or Countries 
 
i. Legislation in the United States 
 
There have been a few key pieces of legislation relating to counterfeit drugs 
in the United States that have helped keep it relatively (in comparison to the 
countries just discussed) well-protected. First is the Prescription Drug Marketing 
Act of 1987, which targeted the supply chain to protect Americans from counterfeit 
drugs.131 This law “provides that prescription drug products manufactured in the 
United States and exported can no longer be reimported, except by the product’s 
manufacturer,” while also setting uniform standards for distribution channels.132 
Obviously, this has not been fully effective, as over three decades later, there are 
still counterfeit drugs making their way into our hospitals, mailboxes, and 
pharmacies. 
More recently enacted is the Drug Quality and Security Act, which was 
signed into law in 2013 by President Obama.133 The idea behind part of this Act is 
to implement a “track-and-trace system” allowing a drug to be tracked from creation 
to reaching the hands of the customer, which would make it more difficult for 
counterfeit drugs to enter the supply stream.134 This was broken down into two 
phases: (1) pharmacies implementing a tracking system by 2015 and (2) putting 
serial numbers on individual units by 2017.135 While the idea behind this is 
admirable as it targets one of the key problems—the supply chain—it is flawed in a 
few ways and is not a panacea. First, it is still placing the cost burden on the 
pharmaceutical companies, which ends up being paid for by the consumer. Second, 
there are several troubling issues with the track-and-trace system that led to it 
creating a false sense of security. The most common system used is the Radio 
Frequency Identification (RFID) device, “which uses information stored and 
remotely retrieved on transponders to provide automatic identification” and “can be 
used to provide serial numbers to confirm the identity of a product.”136 While better 
 
130  Jessica McLaughlin, The United States Isn’t Immune to Counterfeit Drugs, LAW STREET (May 8, 2015), 
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than traditional pedigrees that are more easily forged,137 implementing an RFID 
system can be extremely expensive, costing manufacturers up to $25 million.138 This 
safety measure comes with a high cost, which may not be worth it if that cost drives 
customers to unsafe, but cheaper, places to get their medicine. 
The United States also has the Federal Food, Drug, and Cosmetic Act 
(FDCA). According to this Act, a “counterfeit drug” is a drug, or the container or 
labeling of a drug, that bears some mark, including a trademark, misidentifying its 
“manufacturer, processor, packer, or distributor.”139 The good thing about this Act is 
that it criminalizes making, selling, or dispensing counterfeit drugs.140 The bad 
thing is that the penalties for violating this law are not severe enough to deter the 
counterfeiters, especially when their business is so lucrative. Violators are punished 
with a maximum $1,000 fine and up to one year in prison.141 As stated earlier, 
counterfeiters can make ten times more money than if they were trafficking 
heroin.142 
 
ii. Attempted Remedies in Asia 
 
Despite being the biggest culprits in counterfeit medicine, some Asian 
countries are taking steps against counterfeit drugs. For example, Chinese officials 
have begun investigating and closing factories associated with counterfeit drugs, 
and the police even made arrests in a counterfeit drug conspiracy involving over 
four million dollars’ worth of pills.143 In October 2018, China’s Drug Administration 
Law was reviewed to increase penalties for counterfeit drug makers.144 China has 
also developed stronger intellectual property laws that support both foreign and 
domestic intellectual property rights (IPRs),145 as shown in a “Chinese court 
decision upholding Pfizer's patent rights to the blockbuster drug Viagra.”146 In order 
to remain strong in the global economic market, China will need to continue the 
trend of enforcing IPRs to reduce counterfeiting. Despite increased enforcement in 
China, there are already other countries in Asia that are beginning to become 
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appealing to the counterfeiters, showing that regional and global cooperation is 
necessary to stop these criminals.147 
The other biggest culprit, India, is also making strides in the right direction 
by introducing legislation mandating the barcoding of pharmaceutical products, 
allowing fake drugs to be easily identified.148 In 2018, India took this a step further 
by deploying blockchain technology to improve the traceability of pharmaceutical 
products by creating a database to keep track and help prevent fakes from entering 
the supply chain.149 
Other countries have not taken such direct steps but are still attempting to 
stop this problem. In Myanmar, they started using a “handheld device which can 
assess the compound of a drug in real time.”150 Other countries, such as Thailand, 
Laos, and Cambodia, are addressing the consumers’ lack of awareness.151 
Governments and companies are issuing warnings, developing websites, 
campaigning with multiple forms of media (posters, radio, and television), and 
encouraging press coverage. 152 Instead of attempting to fix the complicated supply 
chain, they are educating their citizens on safe purchasing habits, which is a 
cheaper remedy that tackles the problem from a different angle. 
 
iii. Attempts in Africa 
 
One of the most important steps in stopping this illegal drug trade was the 
establishing of the National Agency for Food and Drug Administration and Control 
(NAFDAC) by the Nigerian Federal Ministry of Health.153 NAFDAC had helped in 
shutting down several counterfeit markets and slowed the importation of fake 
medicine.154 This program was an overall success, and Nigeria managed to reduce 
counterfeit drug circulation by eighty percent by limiting drug importation to only 
two locations and equipping customs officials with the resources to test whether the 
drugs are authentic.155 While this was not a perfect solution, as the counterfeit drug 
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problem is still prevalent in Nigeria, it showed that steps can be taken to lessen the 
severity of the issue. 
The success of this program garnered attention and encouraged other African 
nations to take action. For example, in 2018, Tanzania became “the first confirmed 
country in Africa to achieve a well-functioning, regulatory system for medical 
products.”156 However, much of the progress in other countries has come from the 
hard work of individuals or companies. One individual, Franck Verzefé, from 
Cameroon, developed a portable device that uses artificial intelligence to help 
hospitals and pharmacies determine if a drug is legitimate.157 One of the most 
helpful parts of his invention is the ability to build a database of information to 
allow for more accurate and reliable data on the drug problems in Africa.158 One 
company, Mesdaf, is attempting to fix the supply chain by cutting out middlemen 
and connecting manufacturers directly to hospitals and pharmacies.159 Finally, 
Ghana now has mPedigree, which “uses a simple text message code to help 
customers verify the authenticity of medicines” and feasibly could be used in other 
African countries.160 
 
B. International Collaboration 
 
As counterfeit drugs are a global issue, it makes sense that there would need 
to be international cooperation and collaboration to truly ameliorate this problem. 
One of the most important international attempts at harmonization of IPRs was in 
1994 when World Trade Organization (WTO) member countries signed the Trade-
Related Aspects of Intellectual Property Agreement (TRIPS), which set the 
minimum standards for IPRs.161 At the time, it was thought to be a radical change 
to the international market, but in practice it has not been as aggressive or strict as 
imagined.162 Compliance with TRIPS is not always easy or cheap.163 Before the 
agreement, many developing nations had very little intellectual property protection 
or offered “no form of patent protection to pharmaceutical medicines.”164 After the 
agreement, these countries, many with public health crises, bear the cost of 
implementing the agreement and the increase in drug costs that go with it.165 Since 
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its implementation in 1994, TRIPS has not had a significant impact on stopping the 
counterfeit drug crisis.166 
More recently, in June 2013, almost one hundred countries participated in a 
global action––Operation Pangea VI––to help stop online trading of counterfeit 
drugs.167 Operation Pangea VI helped eliminate close to two thousand websites that 
were selling illegal prescription drugs.168 In July 2013, the Global Surveillance and 
Monitoring System for SF medical products was launched.169 This system works by 
each country relaying information about the counterfeit drug to WHO, which then 
adds it to a database in order to determine the scope of the problem, track patterns, 
and keep the public informed.170 While this is useful knowledge to have, the system 
is fairly passive, does not take any actual steps in addressing the problem, and does 
not allow the data to be freely accessed by the public.171 
 
III. STRONGER TRADEMARK ENFORCEMENT: A POSSIBLE SOLUTION OR AT LEAST A 
STEP IN THE RIGHT DIRECTION? 
 
Consumers are at the core of this whole problem, but that means they are 
important in helping to stop the issues. Many attempts by governments and 
pharmaceutical companies have so far only addressed the supply side with the 
complicated supply chain, which has not been a perfect solution due to its high level 
of complication and high costs. On the other hand, it could be cheaper and more 
effective to try to control what the consumer already knows—the appearance of 
their medicine and the trademarked information associated with it. For brand name 
drugs, trademarks are especially important as they convey to the customer that 
their product is high quality and one to be trusted.172 Trademarks seek to protect 
exactly what counterfeiters target: brand recognition.173 Medicines can have many 
different trademarks. Marks can be obtained on the name, design, and symbols on 
the packaging, along with the color and shape of the pill.174 In this way, 
pharmaceutical companies can protect every unique aspect of the appearance of 
their medicine in addition to any other intellectual property the company has for 
the drug.175 
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Typically, patents on pharmaceuticals are the first line of defense, but in 
practice, they are less effective at stopping counterfeiters. 176 As discussed in Part I, 
the counterfeit drugs are not a copy of the active ingredient (what would be 
patented) but are imposters made of cheaper ingredients.177 Further, trademark 
protection is available to generic drug manufacturers whereas patent rights are 
not.178 Unlike in many patent lawsuits, “in many countries trademark owners can 
have the counterfeit goods and accompanying documents, and even sometimes 
manufacturing equipment immediately seized at the outset of [a] lawsuit,” allowing 
for quicker relief than waiting for a decision in a patent trial that could last 
years.179 Finally, trademarks are the cheaper option and are usually less time 
consuming than patent prosecution or litigation.180 Especially for developing 
countries that need quicker relief and have fewer resources to expend on securing 
and enforcing IPRs, trademarks seem to be the better remedy. 
In an ideal world, these trademarks on pharmaceuticals would be strictly 
enforced, and knockoffs would be prosecuted and removed from the market. 
However, it is not that simple. Right now, many consumers are buying counterfeit 
drugs believing them to be legitimate, and they are doing so due to the high-quality 
packaging and appearance of the counterfeit medicine, making it difficult, 
sometimes impossible, for consumers to be able to spot fake drugs.181 In order for 
companies, especially in developing countries, to invest in trademark protection, 
they need assurance that they are not wasting their money on something that will 
not be enforced, and if it is enforced, it will have meaningful relief for them. With 
stronger trademark enforcement comes more trust from consumers and companies, 
which will both deter people from buying fake drugs and encourage companies to 
develop their trademark portfolios.  
In the United States, trademark owners have had federal causes of action 
against unauthorized use of their marks for many years now.182 However, there is 
not strong enough enforcement against counterfeit trademarked goods in the United 
States as the laws do not wholly cover every instance of counterfeiting, which is 
needed to stop this problem. There are two primary federal statutes, the Lanham 
Act183 and the 1984 Trademark Counterfeiting Act (TCA),184 that created civil and 
criminal liability for trademark infringement. These statutes “define the term 
‘counterfeit’ vaguely and broadly.”185 A counterfeit trademark is a “‘spurious mark’ 
that is ‘identical with, or substantially indistinguishable from, a registered mark,’ 
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and whose use is ‘likely to cause confusion.’”186 The Lanham Act is a broad 
trademark regulator and created civil causes of action for infringement of both 
registered and unregistered marks.187 The TCA, amended by the 2005 Stop 
Counterfeiting in Manufactured Goods Act, took trademark enforcement a step 
further with the addition of criminal penalties for the most serious forms of 
infringement, which Congress considered to be the intentional trafficking of 
counterfeit goods.188 The penalties under this act are fines up to $5 million and 10 
years imprisonment.189  
In the case of counterfeit drugs, this criminalization is beneficial as it targets 
the trafficking of counterfeit drugs, which is the primary problem in America given 
that most of the drugs making it to consumers come from overseas and are illegally 
trafficked into the country. In theory, the TCA would be able to stop all criminals 
trafficking these fake drugs, but the broad definition of a counterfeit mark makes 
this more difficult. Under the TCA a counterfeit mark is one: 
(i) that is used in connection with trafficking in any goods, services, 
labels, patches, stickers, wrappers, badges, emblems, medallions, 
charms, boxes, containers, cans, cases, hangtags, documentation, 
or packaging of any type or nature; 
(ii) that is identical with, or substantially indistinguishable from, a 
mark registered on the principal register in the United States 
Patent and Trademark Office and in use, whether or not the 
defendant knew such mark was so registered; 
(iii) that is applied to or used in connection with the goods or services 
for which the mark is registered with the United States Patent 
and Trademark Office, or is applied to or consists of a label, patch, 
sticker, wrapper, badge, emblem, medallion, charm, box, 
container, can, case, hangtag, documentation, or packaging of any 
type or nature that is designed, marketed, or otherwise intended 
to be used on or in connection with the goods or services for which 
the mark is registered in the United States Patent and Trademark 
Office; and 
(iv) the use of which is likely to cause confusion, to cause mistake, or 
to deceive.190 
When the law was passed, Congress noted that the “definition of 
‘substantially indistinguishable’ will have to be elaborated on a case-by-case basis 
by the courts.”191 The “courts have been reluctant to label a mark a counterfeit, at 
least in the word mark context, when defendant’s mark is not a fairly clear copy of 
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the registered trademark.”192 For example, in one case, the court analyzed a claim 
that a Chinese toothpaste was counterfeit because it was in a red box labeled 
“Colddate” and held that, although the products were “quite similar,” they were not 
“substantially indistinguishable.”193 There seems to be a very fine line between 
infringement and counterfeit, and marks are less likely to be determined counterfeit 
if they are not identical images of the original trademark.194 If anything, this 
encourages counterfeiters to make convincing fake packaging to still trick 
consumers without making it identical so they can escape criminal liability. In order 
for the TCA to help remedy the counterfeit drug issue, the definition of counterfeit 
and the implementation of this definition need to cover both the identical copies and 
those that are still close enough to trick the consumer. 
Although some instances of pharmaceutical counterfeiting fall under the 
Lanham Act or TCA, there are still situations where the criminal will escape 
liability. The laws combatting fake drugs, discussed earlier, offer much weaker 
remedies with “tepid” penalties and no relief to those harmed by the drug.195 Due to 
the extreme danger posed by fake pharmaceuticals, the penalties under the fake 
drug laws are inadequate, and trademark enforcement has been unable to ensure 
enforcement in every case.196 
In addition to trying to control the supply chain, other countries should 
implement their versions of laws criminalizing counterfeit drug trafficking or the 
use of counterfeit marks on pharmaceutical products. Especially for developing 
countries, trademarks are an affordable form of intellectual property that 
consumers are able to identify and trust. With enforcement of these marks, 
countries can keep copycat drugs from reaching consumers while still punishing the 
perpetrators. The Madrid Protocol of 1989, which helped streamline international 
trademark registration between its member countries, allows someone to complete 
one international application and receive protection in participating countries that 
approve the mark as determined by their domestic law.197 In order to encourage and 
help developing countries, the international fee is lowered to ten percent for 
applications originating in the least developed countries as defined by the United 
Nations.198 The Madrid Protocol emphasizes the importance of international 
enforcement of trademarks but still relies on each individual country to enforce 
trademark laws. In some countries, their laws are still outdated and do not 
recognize this international system, so enforcement is even more of an issue. 
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In conclusion, there truly is not one solution for this problem. Greater 
harmonization and coordination internationally are required. Each country faces 
unique issues with specific diseases and the amount of money it can spend on 
protecting and enforcing intellectual property rights. Because counterfeit drugs are 
such a global issue, it is often difficult to pinpoint the source of the fake drug and 
find the criminals behind its creation and distribution. While trademarks are not a 
cure-all, they are a feasible first start for many countries. Trademark enforcement 
has not been perfect in America, but it is one aspect that has allowed the country to 
have the safest drug supply in the world. If consumers are educated on this issue, or 
at least warned about fake drugs, they are likely to be more cautious shoppers, 
which could lead to them making safer decisions on where to get their medicine and 
being skeptical of knock-off products. 
